Enhancement of antitumor immunity by CTLA-4 blockade.
Level 5 - mechanism / opinion, no new human data
Preclinical in vivo animal study.
PubMed 8596936 · doi:10.1126/science.271.5256.1734
What was done
Investigators tested the in vivo administration of blocking antibodies against CTLA-4, a negative regulator of T-cell activation, in tumor-bearing models, evaluating effects on tumor rejection (including preestablished tumors) and subsequent resistance to secondary tumor exposure.
What was found
The abstract provides no quantitative metrics, percentages, or sample sizes. Qualitatively, anti-CTLA-4 antibody administration caused the rejection of tumors, including preestablished tumors, and conferred protective immunity against secondary tumor cell challenge.
Why it matters
This seminal study provided the proof-of-concept for immune checkpoint blockade in oncology, showing that releasing inhibitory signals on T cells can trigger effective antitumor immunity.
Limits
The findings are limited to preclinical animal models and cannot directly establish human clinical efficacy or safety from the abstract. The abstract reports no numerical outcomes, exact experimental protocols, animal strain information, or adverse effect data.
Cited by
- supports Blocking a negative regulatory molecule on T cells using an antibody activates T cells and causes tumors in mice to regress.